Research into the therapeutic benefits of “taboo” substances, such as ketamine, LSD, psilocybin, and cannabis has heated up, with a focus on how they could be used to treat a range of CNS-related disorders. We take a look at the substances themselves, as well as the investors and companies that are driving the surge in scientific attention.
